Cargando…

Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature

BACKGROUND: Papillary thyroid cancer (PTC) is one of the well-differentiated thyroid tumors. Cutaneous metastasis from differentiated thyroid cancers occurs in < 1% of primary thyroid carcinomas but produces the worst survival prognosis. The multi-targeting tyrosine kinase inhibitor anlotinib has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Li-Yong, Cai, Shao-Jun, Liang, Bo-Yan, Yan, Shou-Yi, Wang, Bo, Li, Meng-Yao, Zhao, Wen-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198115/ https://www.ncbi.nlm.nih.gov/pubmed/37214573 http://dx.doi.org/10.12998/wjcc.v11.i12.2839

Ejemplares similares

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat
por: van Velsen, Evert F S, et al.
Publicado: (2023)

Synergic radiosensitization of sinomenine hydrochloride and radioiodine on human papillary thyroid carcinoma cells
por: Zhao, Aomei, et al.
Publicado: (2021)

A 64 year-old female with scalp metastasis of papillary thyroid cancer
por: Aghasi, Mohammad Reza, et al.
Publicado: (2011)

Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?
por: Krčálová, Eva, et al.
Publicado: (2016)

Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
por: Gao, Xuemei, et al.
Publicado: (2016)

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

Papillary Carcinoma Thyroid Presenting as Huge Scalp Metastases
por: Barwad, Adarsh, et al.
Publicado: (2018)

Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma
por: Li, Genpeng, et al.
Publicado: (2022)

New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
por: Wong, Kai-Pun, et al.
Publicado: (2012)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
por: Alsaud, Arwa, et al.
Publicado: (2020)

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
por: Colombo, Carla, et al.
Publicado: (2020)

Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma
por: Kaewchur, Tawika, et al.
Publicado: (2021)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Giant scalp metastasis of follicular carcinoma thyroid
por: Vias, Poorva, et al.
Publicado: (2020)

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients
por: Carballo, Marilee, et al.
Publicado: (2012)

Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
por: Jin, Meihua, et al.
Publicado: (2020)

GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy
por: Barros-Filho, Mateus C., et al.
Publicado: (2020)

Surgical resection following therapy with anlotinib in locally advanced papillary thyroid carcinoma: a case description
por: Zhang, Jing, et al.
Publicado: (2023)

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma
por: Cadena-Piñeros, Enrique, et al.
Publicado: (2022)

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients
por: Buczyńska, Angelika, et al.
Publicado: (2023)

Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study
por: Liu, Hanqing, et al.
Publicado: (2023)

Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy
por: Mishra, Ayush, et al.
Publicado: (2023)

Faecalibacterium prausnitzii in Differentiated Thyroid Cancer Patients Treated with Radioiodine
por: Fernandes, Ana, et al.
Publicado: (2023)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

Papillary Thyroid Cancer in Struma Testis with Malignant Transformation in the Lung Associated with Trisomy 17 Successfully Treated with Total Thyroidectomy and Radioiodine Ablation
por: Barakat, Shadi, et al.
Publicado: (2014)

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
por: Jin, Yuchen, et al.
Publicado: (2017)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

Strongly Radioiodine-Positive Pancreatic Adenocarcinoma Mimicking Metastasis of Differentiated Thyroid Cancer
por: Rosar, Florian, et al.
Publicado: (2022)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023)

Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy
por: Yang, Jing, et al.
Publicado: (2017)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Clinical significance of extra-thyroid (99m)Tc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma
por: Long, Bin, et al.
Publicado: (2021)

Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns
por: Cai, Meng, et al.
Publicado: (2022)

Focal Bronchiectasis Causing Abnormal Pulmonary Radioiodine Uptake in a Patient with Well-Differentiated Papillary Thyroid Carcinoma
por: Gargya, Ash, et al.
Publicado: (2012)

The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Salvage surgery for cervical radioiodine refractory (18)F-FDG-PET positive recurrence of papillary thyroid cancer
por: Chiapponi, C, et al.
Publicado: (2021)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bekpt6d25dlq8di9t34g8s6lsn